Sunitinib in kidney cancer: 10 years of experience and development
暂无分享,去创建一个
Laetitia Mauge | Marc-Olivier Timsit | E. Tartour | S. Oudard | L. Fournier | V. Verkarre | M. Timsit | Stéphane Oudard | Eric Tartour | L. Mauge | Virginie Verkarre | A. Méjean | Elise Nassif | Constance Thibault | Yann Vano | Laure Fournier | Arnaud Mejean | Y. Vano | C. Thibault | E. Nassif
[1] Chad A. LaGrange,et al. Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.
[2] J. Patard,et al. Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. , 2016, The New England journal of medicine.
[3] S. Oudard,et al. Long-term use of sunitinib in metastatic renal cell carcinoma: no unpleasant surprises about tolerability , 2016 .
[4] T. Choueiri,et al. CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: Results from ALLIANCE A031203 trial , 2016 .
[5] P. Hegde,et al. Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Suzanne F. Jones,et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma , 2016, Nature Communications.
[7] S. Oudard,et al. Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma-Results of the REchallenge with SUnitinib in MEtastatic RCC (RESUME) Study. , 2016, European journal of cancer.
[8] J. Manola,et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial , 2016, The Lancet.
[9] P. Tamboli,et al. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. , 2016, European urology.
[10] P. Tamboli,et al. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma , 2016, Oncogene.
[11] L. Devine,et al. Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma , 2016, Cancer Chemotherapy and Pharmacology.
[12] J. Hainsworth,et al. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. , 2016, The Lancet. Oncology.
[13] C. Porta,et al. Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma. , 2016, European urology.
[14] C. Porta,et al. Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] B. Escudier,et al. Sorafenib-Sunitinib Sequence: The Jury Is Out. , 2015, European urology.
[16] J. Ahn,et al. RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] M. Staehler,et al. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer. , 2015, European urology.
[18] Mellar P. Davis,et al. Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients , 2015, British Journal of Cancer.
[19] S. Signoretti,et al. Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor‐risk metastatic renal cell carcinoma , 2015, Cancer.
[20] E. Tartour,et al. Poster Session (Monday, 28 September)Translational ResearchPOSTER223 Predictive biomarkers in metastatic Renal Cell Carcinoma (mRCC) patients treated with neoadjuvant sunitinib (PREINSUT trial) , 2015 .
[21] A. Ravaud,et al. Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] J. Larkin,et al. First-line treatment in the management of advanced renal cell carcinoma: systematic review and network meta-analysis , 2015, Expert opinion on pharmacotherapy.
[23] David C. Smith,et al. Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] A. Ravaud,et al. First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)†. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[25] R. Motzer,et al. Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] I. Derweesh,et al. Presurgical sunitinib reduces tumor size and may facilitate partial nephrectomy in patients with renal cell carcinoma. , 2015, Urologic oncology.
[27] G. Freeman,et al. Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer , 2015, Clinical Cancer Research.
[28] E. Tartour,et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors , 2015, The Journal of experimental medicine.
[29] E. Jonasch,et al. Alternate sunitinib schedules in patients with metastatic renal cell carcinoma. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[30] N. Rioux-Leclercq,et al. Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting , 2015, Clinical Cancer Research.
[31] A. Kiss,et al. Reprint of: Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: Correlation with dynamic microbubble ultrasound data and review of the literature. , 2014, Urologic oncology.
[32] M. van Engeland,et al. Resistance to sunitinib in renal cell carcinoma: From molecular mechanisms to predictive markers and future perspectives. , 2015, Biochimica et biophysica acta.
[33] S. Signoretti,et al. Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial , 2014, Clinical Cancer Research.
[34] H. Kohrt,et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.
[35] Tae Min Kim,et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] C. L. Le Rest,et al. 853PPREDICTION OF RESPONSE OF PRIMARY TUMORS TO NEOADJUVANT SUNITINIB USING PERFUSION (DCE) COMPUTED TOMOGRAPHY (CT) IN METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS (PREINSUT TRIAL). , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[37] B. Redman,et al. A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[38] R. Figlin,et al. Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma , 2014, Cancer Chemotherapy and Pharmacology.
[39] E. Rasmussen,et al. A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma. , 2014, Clinical genitourinary cancer.
[40] E. Plimack,et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). , 2014 .
[41] C. Porta,et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] E. Tartour,et al. Prognostic factors in patients with advanced renal cell carcinoma treated with VEGF-targeted agents , 2014, Expert review of anticancer therapy.
[43] Y. Najjar,et al. A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma. , 2014, European journal of cancer.
[44] T. Bathala,et al. Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules. , 2014, The Journal of urology.
[45] C. Porta,et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[46] A. Kiss,et al. Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature. , 2014, Urologic oncology.
[47] J. Reeves,et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. , 2013, The New England journal of medicine.
[48] B. Neri,et al. Biweekly sunitinib regimen reduces toxicity and retains efficacy in metastatic renal cell carcinoma: A single‐center experience with 31 patients , 2013, International journal of urology : official journal of the Japanese Urological Association.
[49] J. Patard,et al. Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib , 2013, British Journal of Cancer.
[50] E. Ibrahim,et al. Sunitinib adverse events in metastatic renal cell carcinoma: a meta-analysis , 2013, International Journal of Clinical Oncology.
[51] Lisa L. Smith,et al. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. , 2012, European urology.
[52] B. Escudier,et al. Neoadjuvant treatment in advanced renal cell carcinoma: current situation and future perspectives , 2012, Expert review of anticancer therapy.
[53] S. Oudard,et al. Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit. , 2012, Cancer treatment reviews.
[54] C. Sternberg,et al. Dose Escalation and Pharmacokinetics Study of Enzastaurin and Sunitinib Versus Placebo and Sunitinib in Patients With Metastatic Renal Cell Carcinoma , 2012, American journal of clinical oncology.
[55] J. Ahn,et al. Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[56] J. Kaouk,et al. The effect of sunitinib on primary renal cell carcinoma and facilitation of subsequent surgery. , 2012, The Journal of urology.
[57] J. Burke,et al. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] R. Motzer,et al. Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma , 2012, Cancer.
[59] C. Barrios,et al. Phase II trial of continuous once‐daily dosing of sunitinib as first‐line treatment in patients with metastatic renal cell carcinoma , 2012, Cancer.
[60] D. Brizel,et al. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .
[61] D. Berney,et al. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer. , 2011, European urology.
[62] A. Ganser,et al. Efficacy of Sunitinib Re-Exposure after Failure of an mTOR Inhibitor in Patients with Metastatic RCC , 2011, Oncology Research and Treatment.
[63] R. Figlin,et al. Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib , 2011, Journal of the National Cancer Institute.
[64] B. Rini,et al. Phase 1 dose‐escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma , 2011, Cancer.
[65] E. Tartour,et al. Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy , 2011, Cancer and Metastasis Reviews.
[66] J. Haanen,et al. A Phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC) , 2011, Acta oncologica.
[67] G. Wilding,et al. A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate , 2012, Investigational New Drugs.
[68] V. Reuter,et al. Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma , 2012, Investigational New Drugs.
[69] T. Choueiri,et al. Sunitinib rechallenge in metastatic renal cell carcinoma patients , 2010, Cancer.
[70] E. Tartour,et al. A Decrease of Regulatory T Cells Correlates With Overall Survival After Sunitinib-based Antiangiogenic Therapy in Metastatic Renal Cancer Patients , 2010, Journal of immunotherapy.
[71] I. Derweesh,et al. Feasibility and efficacy of neoadjuvant sunitinib before nephron‐sparing surgery , 2010, BJU international.
[72] B. Teh,et al. Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. , 2010, The Journal of urology.
[73] Karl J. Dykema,et al. Reversible Epithelial to Mesenchymal Transition and Acquired Resistance to Sunitinib in Patients with Renal Cell Carcinoma: Evidence from a Xenograft Study , 2010, Molecular Cancer Therapeutics.
[74] G. Demetri,et al. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis , 2010, Cancer Chemotherapy and Pharmacology.
[75] B. Rini,et al. Correction: A Phase I Study of Sunitinib plus Bevacizumab in Advanced Solid Tumors , 2009, Clinical Cancer Research.
[76] Helen X. Chen,et al. A Phase I Study of Sunitinib plus Bevacizumab in Advanced Solid Tumors , 2009, Clinical Cancer Research.
[77] U. Harmenberg,et al. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[78] C. Porta,et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. , 2009, The Lancet. Oncology.
[79] Xin Huang,et al. Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[80] S. Oudard,et al. Salvage therapy with bevacizumab-sunitinib combination after failure of sunitinib alone for metastatic renal cell carcinoma: a case series. , 2009, European urology.
[81] B. Teh,et al. Complexity of tumor vasculature in clear cell renal cell carcinoma , 2009, Cancer.
[82] R. Motzer,et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[83] R. Figlin,et al. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. , 2009, Cancer research.
[84] Masahiro Inoue,et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009, Cancer cell.
[85] R. Motzer,et al. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. , 2008, Clinical genitourinary cancer.
[86] M. Michaelson,et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[87] R. Motzer,et al. Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[88] Gabriele Bergers,et al. Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.
[89] C. Charbonneau,et al. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. , 2008, Cancer treatment reviews.
[90] M. Koch,et al. Tumor Escape from Endogenous, Extracellular Matrix–Associated Angiogenesis Inhibitors by Up-Regulation of Multiple Proangiogenic Factors , 2008, Clinical Cancer Research.
[91] F. Kabbinavar,et al. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period , 2008, Cancer Chemotherapy and Pharmacology.
[92] J. Christensen,et al. A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[93] Phillip H. Lai,et al. Sunitinib (Sutent®): A novel agent for the treatment of metastatic renal cell carcinoma , 2007, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
[94] L. Chow,et al. Sunitinib: from rational design to clinical efficacy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[95] R. Figlin,et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.
[96] N. Normanno,et al. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. , 2006, The oncologist.
[97] R. Motzer,et al. Sunitinib in patients with metastatic renal cell carcinoma. , 2006, JAMA.
[98] R. Figlin,et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[99] E. Raymond,et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[100] Randy Allred,et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. , 2005, Blood.
[101] M. Krzakowski,et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[102] E. Messing,et al. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. , 2003, The Journal of urology.
[103] Juthamas Sukbuntherng,et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[104] R. Motzer,et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[105] A. Ravaud,et al. Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma , 1998 .
[106] A. Ravaud,et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie. , 1998, The New England journal of medicine.
[107] E. Tartour,et al. Variable expression of CD3‐ζ chain in tumor‐infiltrating lymphocytes (TIL) derived from renal‐cell carcinoma: Relationship with til phenotype and function , 1995 .
[108] R. Fisher,et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.